Shu-Hua Yi
Overview
Explore the profile of Shu-Hua Yi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
56
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cao X, Jin J, Fu C, Yi S, Zhao W, Sun Z, et al.
EClinicalMedicine
. 2022 Oct;
52:101682.
PMID: 36313145
Background: Orelabrutinib is a novel, small molecule, selective irreversible Bruton tyrosine kinase inhibitor. The purpose of this study was to evaluate the efficacy and safety of orelabrutinib in patients with...
2.
Liu J, Fan H, Yan W, Xu J, Li L, Xu Y, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
. 2022 Oct;
30(5):1453-1463.
PMID: 36208249
Objective: To investigate the clinical value of oligoclonal bands (OB) in patients with multiple myeloma (MM). Methods: The laboratory test and clinical data of 624 newly diagnosed MM patients admitted...
3.
Yi S, Chen S, Li Y, Hu Z
Ying Yong Sheng Tai Xue Bao
. 2022 Aug;
33(8):2271-2278.
PMID: 36043836
Ecologically fragile areas account for more than 60% of land area in China. Global change and human activities are aggravating ecosystem degradation and reducing the carrying capacity of resources and...
4.
Zhang N, Jiang T, Yi S
World J Clin Cases
. 2022 Jun;
10(14):4698-4703.
PMID: 35663063
Background: Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder. Plasma cell dyscrasias are a rare heterogeneous group of hematological disorders. The co-occurrence of CML and plasma cell...
5.
Sun Y, Qin Y, Wei T, Chang L, Zhang R, Liu Z, et al.
Ying Yong Sheng Tai Xue Bao
. 2022 May;
33(3):655-663.
PMID: 35524516
Plant species diversity is one of the critical factors for maintaining multi-function and stability of terrestrial ecosystem. We reviewed the traditional methods for measuring plant species diversity of grassland (PSDG),...
6.
Cao X, Yi S, Jiang Z, He J, Yang W, Du J, et al.
Leuk Lymphoma
. 2021 Jun;
62(11):2657-2664.
PMID: 34105439
In this study, we aimed to investigate treatment options and the prognosis of patients with WM in China. This retrospective study included 1141 patients diagnosed with symptomatic WM between January...
7.
Zhang Y, Yu Z, Xiong W, Liu X, Liu H, Cui R, et al.
Chin Med J (Engl)
. 2020 Aug;
133(17):2090-2097.
PMID: 32784334
Background: TOSO, also named Fas inhibitory molecule 3 (FAIM3), has recently been identified as an immunoglobulin M (IgM) Fc receptor (FcμR). Previous studies have shown that TOSO is specifically over-expressed...
8.
Mao X, Zhuang J, Zhao D, Li X, Du X, Hao M, et al.
Eur J Haematol
. 2020 May;
105(3):326-334.
PMID: 32421883
Background: In multiple myeloma (MM), impact of specific chromosomal translocations involving IgH (14q21 locus, including t(4;14), t(11;14), and t(14;16)) has been explored extensively. However, over 15% MM patients harboring IgH...
9.
Lu R, Li Z, An G, Yi S, Liu W, Wang T, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
. 2019 Jun;
27(3):839-843.
PMID: 31204941
Objective: To investigate the clinical characteristics and therapeutic responte of patients with B-CLPD mainly manifested as cytopenia, so as to deeply understand this disease. Methods: The clinical data of 13...
10.
Qin X, An G, Li Z, Liu L, Xu Y, Yang L, et al.
Blood Adv
. 2019 Mar;
3(5):751-760.
PMID: 30833275
The treatment of multiple myeloma (MM) with proteasome inhibitor (PI) bortezomib has significantly improved the survival of patients with MM. The 26S proteasome inhibitor targets the unfolded protein response (UPR)...